Attovia Therapeutics: $90 Million (Series C) Raised For Developing Treatments For Immune-Mediated Diseases
By Amit Chowdhry ● Today at 4:40 PM
Attovia Therapeutics, a privately-held, clinical-stage biopharma company developing treatments for immune-mediated diseases with high unmet patient need, announced the closing of a $90 million Series C funding. Deep Track Capital led this funding round with participation from new investors including Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, and ongoing support from existing investors including Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, and Illumina Ventures.